Tue Dec 17 11:40:00 UTC 2024: **Pfizer Stock: A Dividend Boost Amidst Market Underperformance**

NEW YORK, NY – Pfizer (NYSE:PFE), a pharmaceutical giant with a history dating back to 1849, announced a 2.4% dividend increase, raising its payout to $0.43 per share. While this offers a welcome boost (forward dividend yield of 6.7%), the stock itself has underperformed, down 13% year-to-date and 30% over the last five years.

Despite the downturn, Pfizer remains a leading biopharmaceutical company, contributing significantly to healthcare throughout history. Its current revenue streams are diverse, with Eliquis (anticoagulant) representing approximately 22% of total revenue, and Comirnaty (COVID-19 vaccine) and Paxlovid (COVID-19 antiviral) contributing another 21%. Other key products include Prevnar 13 (pneumococcal vaccine), Ibrance (breast cancer treatment), and Vyndaqel/Vyndamax (heart condition treatment). The company is also developing a Lyme disease vaccine expected for regulatory approval in 2026.

While Pfizer’s Oncology division saw a 31% year-over-year revenue increase, and strong earnings guidance is anticipated for next year, concerns remain about patent expiries and the high cost of R&D ($10 billion annually). These factors, along with past controversies surrounding its COVID-19 vaccine, have contributed to the stock’s underperformance, according to analysts. Despite this, some investors believe the stock is undervalued, given Pfizer’s robust pipeline and market position.

**Note:** The original text also included unrelated promotional material for an AI stock investment opportunity and discussion of gold prices, which have been excluded from this news article focusing solely on Pfizer’s financial performance and outlook.

Read More